Physician profile
Mitchell D Silver
NPI 1174502397
$4,699.18
in general payments reported to CMS, 2019-2025
19 companies · $3,211 in 2025
The $3,211 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $174 · 2021: $405 · 2022: $213 · 2023: $119 · 2024: $104 · 2025: $3,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753 · Travel and Lodging: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.10 |
| Travel and Lodging | $1,680.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,211.57 | 2021-2025 | Mo.Ma Ultra, Protege Rx, Spiderfx |
| Intuitive Surgical, INC. | $826.72 | 2025 | |
| Cook Medical LLC | $261.52 | 2019-2022 | |
| Amgen INC. | $253.75 | 2019-2024 | Repatha |
| Endologix LLC | $159.49 | 2021 | |
| Stryker Corporation | $134.81 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $132.69 | 2019-2022 | |
| Kci USA, INC. | $124.75 | 2019 | |
| Medtronic Vascular, INC. | $119.88 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $86.88 | 2024-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $86.67 | 2022-2024 | Watchman Flx |
| Abbott Laboratories | $81.28 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $58.99 | 2019-2020 | |
| Novo Nordisk INC | $42.42 | 2023 | Ozempic |
| Abiomed | $36.13 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $25.81 | 2023 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $20.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.46 | 2022 | |
| Pfizer INC. | $15.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.